In conclusion, our sequence-to-drug concept has successfully identified new scaffolds targeting the protein of interest SPOP, among which 230D7 showed therapeutic potential for blocking SPOP activity to treat ccRCC. Here, SPOP is linked to nonpapillary renal cell carcinoma.